secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001104659-25-012546
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon FY2024 revenue $6.4B (+2%); guides FY2025 revenue $6.125-6.325B
-----------------------------------------------------------------------

- Full year 2024 revenue $6,401M (+2% as-reported, +3% constant currency); diluted EPS $3.33; non-GAAP adjusted diluted EPS $4.11.
- Q4 revenue $1,592M flat YoY; net income $109M vs $546M (down 80%) due to prior-year one-time gain; adjusted net income $235M (+4%).
- FY2025 guidance: revenue $6,125M-$6,325M (incl. ~$200M FX headwind); Adjusted EBITDA margin 31-32% (FY2024: 30.6%).
- Biosimilars Q4 revenue down 18% on tender timing and U.S. pricing pressure; Women's Health flat as Nexplanon +12% offset NuvaRing decline.
- Established Brands +2% driven by Emgality (Lilly license) and Vtama (Dermavant acquisition closed Oct 2024), partly offset by Atozet LOE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465925012546/0001104659-25-012546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465925012546/tm256470d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-012546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer